Back HIV/AIDS

HIV / AIDS

CROI 2016: More People with HIV Are Achieving Viral Suppression in U.S.

A growing proportion of people with HIV are reaching an undetectable viral load on antiretroviral therapy (ART), according to a pair of studies from the U.S. Centers for Disease Control and Prevention (CDC) presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. Despite this improvement, however, a substantial number of people are still not achieving viral suppression, putting them at risk for disease progression and onward transmission.

alt

CROI 2016: Antidepressant Improves HIV-Related Cognitive Impairment

The SSRI antidepressant paroxetine (Paxil) was associated with a modest improvement in cognitive function and reduced central nervous system inflammation among people with HIV-related neurocognitive disorder, but the antifungal drug fluconazole showed no apparent benefit even though it reduced oxidative stress, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston.

alt

NIAID To Fund Follow-Up Study of Dapivirine Vaginal Ring for HIV Prevention

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, will support an open-label continuation study of the dapivirine vaginal ring that demonstrated modest protection against HIV infection, especially among older women, in 2 clinical trials in Africa, as reported at the recent Conference on Retroviruses and Opportunistic Infections in Boston.

alt

England's PrEP Policy in Disarray After National Health Service Turnaround

Activists, individuals at risk of HIV, and clinicians have reacted with anger to an official U-turn on provision of HIV pre-exposure prophylaxis (PrEP) in England, where National Health Service (NHS) officials have refused to allow a draft policy on PrEP to go forward for further consideration. "By denying full availability of PrEP we are failing those who are at risk of HIV," commented Ian Green of Terrence Higgins Trust, a leading U.K. HIV/AIDS organization. "PrEP has already been approved in the U.S., Kenya, South Africa, Israel, Canada, and France. And yet, our own government refuses to take responsibility for PrEP."

alt

CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study

A long-acting bioengineered "combinectin" molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any of the 3 separate mechanisms in a laboratory study, and lowered viral load in humanized mice, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

CROI 2016: Women and African Americans with HIV Have a Higher Risk of Stroke

The risk of stroke among people living with HIV is highest among people with unsuppressed viral load, and among women and African Americans, according to findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

CROI 2016: High STI Rates Among Gay Men on PrEP Supports More Frequent Monitoring

Participants taking tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) continued to have high rates of sexually transmitted infections (STIs) in 2 U.S. PrEP demonstration projects, according to a pair of reports at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. Semi-annual STI testing missed many cases, leading researchers to suggest that gay men on PrEP could benefit from screening every 3 months.

alt